APA (7th ed.) Citation

R, S., J, H., L, Y., B, W., J, S., H, B., . . . S, D. (2024). Design, Synthesis, and Preclinical Evaluation of a High-Affinity 18F-Labeled Radioligand for Myocardial Growth Hormone Secretagogue Receptor Before and After Myocardial Infarction. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 65(10), 1633. https://doi.org/10.2967/jnumed.124.267578

Chicago Style (17th ed.) Citation

R, Sullivan, et al. "Design, Synthesis, and Preclinical Evaluation of a High-Affinity 18F-Labeled Radioligand for Myocardial Growth Hormone Secretagogue Receptor Before and After Myocardial Infarction." Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine 65, no. 10 (2024): 1633. https://doi.org/10.2967/jnumed.124.267578.

MLA (9th ed.) Citation

R, Sullivan, et al. "Design, Synthesis, and Preclinical Evaluation of a High-Affinity 18F-Labeled Radioligand for Myocardial Growth Hormone Secretagogue Receptor Before and After Myocardial Infarction." Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, vol. 65, no. 10, 2024, p. 1633, https://doi.org/10.2967/jnumed.124.267578.